Cabaletta regulatory update

FDA granted Fast Track designation to Cabaletta from BioBlast to treat oculopharyngeal muscular dystrophy (OPMD). The compound is in the Phase II/III HOPE trial for OPMD, for which it has Orphan Drug ...